跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 1,201 条关于
“CDK4/CDK6”
全部
1,201
临床试验
697
药物
219
机构
0
资讯
285
10个月前
Biotheryx Completes Enrollment in Phase 1a Trial of First-in-Class CDK4/6 Degrader BTX-9341 for HR+/HER2- Breast Cancer
6个月前
Biotheryx Advances BTX-9341 CDK4/6 Degrader into Dose Expansion Phase for HR+/HER2- Breast Cancer
去年
Monte Rosa Presents Promising Preclinical Data for CDK2 Molecular Glue Degrader in HR-Positive Breast Cancer at AACR 2025
去年
Ribociclib (Kisqali) Gains Category 1 Recommendation for Early Breast Cancer Treatment
去年
Lilly's Imlunestrant Phase 3 EMBER-3 Data to be Presented at SABCS 2024
去年
FDA Clears Avenzo Therapeutics' IND for AVZO-023, a Novel CDK4 Selective Inhibitor for Advanced Breast Cancer
去年
Inavolisib Triplet Therapy Doubles Progression-Free Survival in Advanced Breast Cancer
去年
Ribociclib Gains NCCN Recommendation as Preferred Adjuvant Therapy for Early Breast Cancer
去年
Clinical Trial Protocol Hints at Bioavailability of Palbociclib Form A, Influencing Patent Revocation
去年
Inavolisib Combination Therapy Doubles Progression-Free Survival in Advanced Breast Cancer
第 1 页,共 29 页
上一页
下一页